Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

NCT04803227 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Unforeseeable difficulties in recruiting patients. There were no reported serious adverse events.

Conditions

Covid19

Interventions

DRUG: Emricasan
OTHER: Placebo

Sponsor

Histogen